In a bold move that blurs the line between consumer fitness tech and medical diagnostics, Whoop has begun accepting users into its new “Advanced Labs” blood testing service, claiming a waitlist of 350,000 individuals eager to integrate their wearable data with biomarker insights. The service, which partners with Quest Diagnostics and comes with annual subscription tiers ranging from $199 to $599, blends continuous monitoring of metrics like sleep, heart rate variability, and respiratory rate with periodic blood panels covering 65+ biomarkers, from hormones to inflammation to lipids. Whoop positions Advanced Labs not just as data delivery, but as coaching guidance embedded in its ecosystem. As it enters a maturing wellness-as-service space crowded with challengers like Function Health and Superpower, the company confronts both opportunities—and scrutiny—over consumer demand, data privacy, medical legitimacy, and potential overreach. In a broader context, this launch reflects the rising tension between wellness startups and traditional healthcare, as Silicon Valley ventures edge into diagnostics, tapping into consumer desire for control over health while testing the boundaries of regulatory oversight.
Sources: WHOOP.com, Fierce Healthcare
Key Takeaways
– Whoop’s Advanced Labs marries wearable data with clinical blood biomarkers in a subscription model, signaling its shift from hardware provider toward health services.
– The growing competition in personalized diagnostics—from Function Health to Superpower—underscores both market demand and challenges around medical credibility, pricing, and consumer trust.
– As wellness companies push deeper into health diagnostics, they face increasing scrutiny over data privacy, regulatory boundaries, and claims of clinical utility.
In-Depth
When Whoop first teased its Advanced Labs offering earlier this year, observers saw it as a logical extension of its current fitness tracking ecosystem. But now that it’s officially open—with a gargantuan 350,000-person waitlist—the move is becoming a litmus test for how far wearable companies can push into health diagnostics. At its core, Advanced Labs partners with Quest Diagnostics to deliver periodic blood panels covering more than 65 biomarkers (like lipids, inflammatory markers, hormone levels) and integrates those results with Whoop’s continuous monitoring engine, which tracks sleep trends, heart rate variability, resting heart rate, and respiratory rate. Users don’t simply get lab results; the service promises clinician-reviewed reports, contextual insights, and coaching recommendations within Whoop’s app interface.
The price is steep, though unsurprising for what’s effectively a hybrid diagnostics plus coaching product: $199 for one test per year, $349 for two, or $599 for four. Considering that Whoop’s wearable membership itself can run $200 to $350 annually depending on the plan, this signals a push toward bundling recurring health services rather than just selling sensors. It mirrors moves by other startups: Superpower recently raised $30 million to offer biannual lab testing across 100+ biomarkers, bundling analytics and personalized plans. Function Health—cofounded by Dr. Mark Hyman—offers a suite of tests and diagnostic insights, positioning itself as a one-stop proactive health platform, with reports of users undergoing 105 tests in a single round. These companies are betting that consumers will pay to peer deeper into their biology.
But this ambition doesn’t come without tension. First, there’s the question of claim creep: how much weight can everyday users place on these biomarker readings when they lack medical supervision, and how much coaching content remains speculative or suggestive rather than strictly evidence-based? Whoop explicitly disclaims that Advanced Labs does not constitute medical advice or diagnosis. More broadly, the space of wellness diagnostics is becoming crowded, and that competitiveness invites scrutiny. Some critics argue that early entrants may overpromise, leading to user confusion, overtesting, and misinterpretation of lab results.
Data privacy is another shadow hanging over these platforms. When wearables collect sleep, heart metrics, movement, and now biomarkers, the sensitivity of the combined dataset is profound. The question of how the data is stored, used, or shared—with insurers, third-party research, or advertisers—will draw increasing regulatory attention. Indeed, we already see tension in adjacent fields: continuous glucose monitors sold direct to consumers have stirred debates over their classification as medical devices versus wellness tools. Combined with lab data, the regulatory line becomes blurrier.
From a market perspective, Whoop’s large built-in user base gives it a strong starting point. The waitlist alone reads like demand validation. If it can execute without too many false promises or backlash, it may set a blueprint for other wearable firms seeking greater monetization beyond hardware margins. But missteps—either perceived overreach, privacy mismanagement, or regulatory scrutiny—could provoke backlash. In that sense, Whoop’s gamble is not merely about offering lab services—it’s testing how much of the healthcare domain consumers and regulators will permit tech companies to colonize.